4-((1E)-2-(6-(2-)2-(2-FLUOROETHOXY)ETHOXY)ETHOXY)PYRIDIN-3-YL)ETHENYL)-N-METHYLBENZENAMINE
Major Depressive Disorder
Chang Gung Memorial HospitalSmall moleculePhase 2Dormant
CCC
51/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 65/ 100
Competitive context
130 Active assets in the Major Depressive Disorder cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
EDIVOXETINE Eli Lilly and Company | Phase 3 | BBB |
(1S,2R)-MILNACIPRAN Allergan | Phase 4 | BBB |
DESVENLAFAXINE Pfizer | Phase 4 | BBB |
17.BETA.-(1-KETOETHYL)-.DELTA. SUP(5)-ANDROSTEN-3.BETA.-OL Massachusetts General Hospital | Phase 4 | BBB |
Duloxetine Alar Pharmaceuticals Inc. | Phase 4 | BB |
View all 50 →
Same molecule, other indications
4-((1E)-2-(6-(2-)2-(2-FLUOROETHOXY)ETHOXY)ETHOXY)PYRIDIN-3-YL)ETHENYL)-N-METHYLBENZENAMINE is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →